Sn60wf

To emulate cataract surgery in post-SMILE eyes, a theoretical calculation model was presented. It is assumed that all patients are implanted with monofocal IOL (SN60WF, Alcon Laboratories, Inc.) with the following constants: for Haigis, a0 = 1.839, a1 = 0.4, and a2 = 0.1, and 118.9 for the other formulas. The Haigis formula was used for calculating the pre-SMILE IOL power. The post-SMILE IOL power was calculated using four methods, including the FY-L formula, the Barrett True-K no history formula, the EVO-L formula, and the Shammas-L formula, respectively. The Barrett True-K no history formula was calculated in two modes, including using the predicted corneal power of the posterior surface (PPCP) and the actual measured corneal power of the posterior surface (MPCP). For the post-SMILE IOL calculation of the same eye, the IOL power targeting the pre-SMILE eyes' lowest myopic refractive error was used.
The FY-L formula used the Actual Ka + p method to modify the measured corneal power (15 (link)). The corneal power was calculated as follows: K_corrected = 1.114 × (K_flattest + K_steepest)/2 + K_posterior, where K_flattest and K_steepest were measured by the IOL master 700, and K_posterior was measured by Pentacam.
To predict the ELP, the FY-L formula was based on the FY-IOL formula, which uses the ACD, anterior and posterior corneal power, LT, and AL for calculation.

The preoperative examination and surgery were strictly performed according to established outpatient surgical procedures in all patients. The same operating room was used for all procedures with the same surgical equipment and instruments. Tropicamide was administered 30 min before surgery to fully dilate the pupil. The conjunctival sac was rinsed with povidone iodine (0.02%) 5 min before surgery. Topical anesthesia consisted of 3 applications of 2% lidocaine before surgery, 1-2 drops per time, with the first application 5 min before surgery, the second application at 1 min before surgery, and the final application after placing the eyelid retractor. Oral and intravenous sedatives or analgesics were not permitted. All procedures were performed by the same right-handed surgeon (Yi Lu).
After topical anesthesia, a 2.6 mm temporal clear corneal incision was created, followed by viscoelastic (DisCoVisc; Alcon Laboratories, Inc., Fort Worth, TX, USA) injection and 5.5 mm continuous curvilinear capsulorhexis. Hydrodissection, chopping, nucleus rotation, and phacoemulsification were then performed. A foldable intraocular lens (SN60WF; Alcon Laboratories, Inc.) was implanted using a dedicated injector. After aspiration of residual viscoelastic, the incision was hydrated with balanced salt solution and checked for water tightness.